PE20110028A1 - Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato - Google Patents
Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamatoInfo
- Publication number
- PE20110028A1 PE20110028A1 PE2010001111A PE2010001111A PE20110028A1 PE 20110028 A1 PE20110028 A1 PE 20110028A1 PE 2010001111 A PE2010001111 A PE 2010001111A PE 2010001111 A PE2010001111 A PE 2010001111A PE 20110028 A1 PE20110028 A1 PE 20110028A1
- Authority
- PE
- Peru
- Prior art keywords
- isoxazole
- dihydro
- chloro
- alkyl
- metabotropic glutamate
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title abstract 3
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title abstract 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003623 enhancer Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 PYRROLIDINE-1-CARBONYL Chemical class 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/08—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
- A61B17/083—Clips, e.g. resilient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/08—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
- A61B17/085—Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound with adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/10—Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/10—Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
- A61B17/105—Wound clamp magazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Surgery (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE ISOXAZOL DE FORMULA (I) DONDE R1 ES ALQUIL(C1-C3) O HALOGENO; R2 ES ALQUIL(C1-C3), HALOALQUIL(C1-C3) O CICLOALQUIL(C3-C6); R3 Y R4 SON CADA UNO H, ALQUIL(C1-C3), HIDROXIALQUIL(C1-C3), CARBOCICLIL(C3-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5-(7-CLORO-2-((S)-1-CICLOPROPILETIL)-1-OXO-2,3-DIHIDRO-1H-ISOINDOLIN-5-IL)-N-METILISOXAZOL-3-CARBOXAMIDA, 5-(7-CLORO-2-((S)-1-CICLOPROPILETIL)-1-OXO-2,3-DIHIDRO-1H-ISOINDOLIN-5-IL)-N,N-DIMETILISOXAZOL-3-CARBOXAMIDA, 7-CLORO-2-ISOPROPIL-5-[3-(PIRROLIDINA-1-CARBONIL)-ISOXAZOL-5-IL]-2,3-DIHIDRO-ISOINDOL-1-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES METABOTROPICOS DE GLUTAMATO (mGluR) SIENDO UTILES EN EL TRATAMIENTO DE ESQUIZOFRENIA, ENFERMEDAD DE PARKINSON, PSICOSIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5948508P | 2008-06-06 | 2008-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110028A1 true PE20110028A1 (es) | 2011-02-11 |
Family
ID=41398335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010001111A PE20110028A1 (es) | 2008-06-06 | 2009-06-08 | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato |
Country Status (40)
| Country | Link |
|---|---|
| US (4) | US7790760B2 (es) |
| EP (2) | EP2303872B1 (es) |
| JP (2) | JP5476371B2 (es) |
| KR (1) | KR20110020797A (es) |
| CN (1) | CN102105466B (es) |
| AR (1) | AR072016A1 (es) |
| AU (1) | AU2009255784B2 (es) |
| BR (1) | BRPI0913585A2 (es) |
| CA (1) | CA2726925A1 (es) |
| CL (1) | CL2010001348A1 (es) |
| CO (1) | CO6321239A2 (es) |
| CR (1) | CR11826A (es) |
| CU (1) | CU23883B1 (es) |
| CY (1) | CY1115301T1 (es) |
| DK (1) | DK2303872T3 (es) |
| DO (1) | DOP2010000375A (es) |
| EA (2) | EA201300342A1 (es) |
| EC (1) | ECSP10010662A (es) |
| ES (1) | ES2469837T3 (es) |
| GT (1) | GT201000342A (es) |
| HK (1) | HK1201255A1 (es) |
| HN (1) | HN2010002582A (es) |
| HR (1) | HRP20140451T1 (es) |
| IL (1) | IL209622A0 (es) |
| MX (1) | MX2010012949A (es) |
| MY (1) | MY156552A (es) |
| NI (3) | NI201000209A (es) |
| NZ (1) | NZ590344A (es) |
| PE (1) | PE20110028A1 (es) |
| PL (1) | PL2303872T3 (es) |
| PT (1) | PT2303872E (es) |
| RS (1) | RS53392B (es) |
| SA (1) | SA109300358B1 (es) |
| SI (1) | SI2303872T1 (es) |
| SV (1) | SV2010003751A (es) |
| TW (3) | TWI477499B (es) |
| UA (1) | UA107649C2 (es) |
| UY (1) | UY31870A (es) |
| WO (1) | WO2009148403A1 (es) |
| ZA (1) | ZA201008611B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | ļ¼ļ¼ļ¼-äŗå代ä¹ļ¼-ę°°åŗ-å”å¶é ®č”ēē©åå ¶ä½ēŗļ½ļ¼§ļ½ļ½ļ¼²ļ¼-åé«ä¹ę£åē°ä½ę§čŖæēÆåä¹ēØé |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| AU2008297877C1 (en) | 2007-09-14 | 2013-11-07 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones |
| EP2203439B1 (en) | 2007-09-14 | 2011-01-26 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-Ć½1, 4'ĀØbipyridinyl-2'-ones |
| SA109300358B1 (ar) * | 2008-06-06 | 2012-11-03 | Ų§Ų³ŲŖŲ±Ų§Ų²ŁŁŁŁŲ§ Ų§ŁŁ ŲØŁ | Ł ŁŁŁŲ§ŲŖ Ł Ų³ŲŖŁŲØŁ Ų¬ŁŁŲŖŲ§Ł Ų§ŲŖ Ų°Ł Ų§ŁŲŖŲŲ§Ų” Ų£ŁŲ¶Ł Ł Ł Ų£ŁŲ²Ł Ų„ŁŲÆŁŁŁŁ |
| MX2011002042A (es) | 2008-09-02 | 2011-06-20 | Ortho Mcneil Janssen Pharm | Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico. |
| ES2466341T3 (es) | 2008-10-16 | 2014-06-10 | Janssen Pharmaceuticals, Inc. | Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrĆ³picos |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP5707390B2 (ja) | 2009-05-12 | 2015-04-30 | ćøć£ć³ć»ć³ ćć”ć¼ćć·ć„ć¼ćć£ć«ć«ćŗļ¼ ć¤ć³ć³ć¼ćć¬ć¤ććć | ļ¼ļ¼ļ¼ļ¼ļ¼āććŖć¢ć¾ćļ¼»ļ¼ļ¼ļ¼āļ½ļ¼½ććŖćøć³čŖå°ä½ććć³ļ½ļ¼§ļ½ļ½ļ¼²ļ¼å容ä½ć®ę£ć®ć¢ćć¹ććŖććÆčŖæēÆå åćØćć¦ć®ćć®ä½æēØ |
| EP2430022B1 (en) | 2009-05-12 | 2013-11-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| WO2012062750A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | Ł Ų±ŁŲØŲ§ŲŖ 6Ų 7- Ų«Ų§ŁŁ ŁŁŲÆŲ±Ł ŲØŁŲ±Ų§Ų²ŁŁŁ [5Ų1-a] ŲØŁŲ±Ų§Ų²ŁŁ- 4 (5 ŁŲÆ)- Ų§ŁŁ ŁŲ§Ų³ŲŖŲ®ŲÆŲ§Ł ŁŲ§ ŲØŲµŁŲ© Ł ŁŲøŁ Ų§ŲŖ ŲŖŁŲ§Ų±ŲŗŁŲ© Ų³ŁŲØŁŲ© ŁŁ Ų³ŲŖŁŲØŁŲ§ŲŖ Ł ŁŲ¬ŁŁŲ± 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | Ł Ų±ŁŲØŲ§ŲŖ 2Ų1Ų 4- Ų«ŁŲ§Ų«Ł Ų²ŁŁŁ [3Ų4-a] ŲØŁŲ±ŁŲÆŁŁ ŁŲ§Ų³ŲŖŲ®ŲÆŲ§Ł ŁŲ§ ŲØŲµŁŲ© Ł ŁŲøŁ Ų§ŲŖ ŲŖŁŲ§Ų±ŲŗŁŲ© Ł ŁŲ¬ŲØŲ© ŁŁ Ų³ŲŖŁŲØŁŲ§ŲŖ Ł ŁŲ¬ŁŁŲ± 2 |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosteriÄne modulatore ili ortosteriÄne agoniste metabotropnog glutamatergiÄnog receptora podtipa 2 i njihova primjena |
| AU2015208233B2 (en) | 2014-01-21 | 2019-08-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| WO2015157187A1 (en) | 2014-04-06 | 2015-10-15 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof |
| KR101663662B1 (ko) * | 2015-06-17 | 2016-10-14 | ķźµź³¼ķźø°ģ ģ°źµ¬ģ | ėģ¬ģ± źøė£Øķė©ģ“ķø ģģ©ģ²“ 1ģ ķģ±ģ ģ§ė ģ ź· ģė¦“ ģģ“ģģ„ģ¬ģ”ø ģ ėģ²“ |
| US20170145002A1 (en) * | 2015-11-25 | 2017-05-25 | Astrazeneca Ab | Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators |
| WO2020102150A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
| US11078204B2 (en) | 2018-11-13 | 2021-08-03 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
| WO2020102216A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Substituted heterocyclic derivatives as pi3k inhibitors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE620654C (de) | 1933-04-29 | 1935-10-24 | Smith & Sons Ltd S | Geschwindigkeitsanzeiger |
| US3993617A (en) | 1975-10-30 | 1976-11-23 | Morton-Norwich Products, Inc. | Antifungal 2-substituted phthalimidines |
| US5175157A (en) | 1985-11-27 | 1992-12-29 | Boehringer Ingelheim Gmbh | Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them |
| WO1992017448A1 (fr) | 1991-04-01 | 1992-10-15 | Kyowa Hakko Kogyo Co., Ltd. | Derive de 3-methylenisoindolin-1-one |
| TW219935B (es) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| EP0602814A1 (en) | 1992-12-18 | 1994-06-22 | Takeda Chemical Industries, Ltd. | Crystal forms of optically active isoindolines and their use |
| US5681954A (en) | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
| CA2245586A1 (en) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| US6417362B1 (en) | 1997-05-30 | 2002-07-09 | Meiji Seika Kaisha, Ltd. | Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same |
| EP1037878A2 (en) | 1997-11-21 | 2000-09-27 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| DE60129210T2 (de) | 2000-02-29 | 2008-03-20 | Mitsubishi Pharma Corp. | Zyklische amid-derivate |
| BR0112856A (pt) | 2000-07-31 | 2003-07-01 | Smithkline Beecham Plc | MĆ©todo para o tratamento dos distĆŗrbios, composto ou um sal ou solvato deste, processo para a preparaĆ§Ć£o dos mesmos, composiĆ§Ć£o farmacĆŖutico, mĆ©todo de tratamento e/ou profilaxia de um ou mais dos distĆŗrbios, uso de um composto, e, mĆ©todo para o tratamento de diabetes, grande depressĆ£o, depressĆ£o manƬaca, ansiedade, esquizofrenia e distĆŗrbios do sono, em mamƬferos humanos e nĆ£o humanos |
| PL368129A1 (en) | 2001-08-09 | 2005-03-21 | Ono Pharmaceutical Co, Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| AU2003226927A1 (en) | 2002-04-09 | 2003-10-27 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
| FR2840302B1 (fr) | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue CarbonsƤureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB0223232D0 (en) | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
| JP2006521358A (ja) | 2003-03-26 | 2006-09-21 | ć”ć«ćÆććØć³ććć«ć ććć¼ćć¤ć³ć³ć¼ćć¬ć¼ććć | 代č¬čŖæēÆåć°ć«ćæćć³é øå容ä½ć®ćć³ćŗć¢ććć¢ćøć„ć¬ć¼ćæ |
| GB0308025D0 (en) | 2003-04-07 | 2003-05-14 | Glaxo Group Ltd | Compounds |
| US7129260B2 (en) | 2003-06-02 | 2006-10-31 | Abbott Laboratories | Isoindolinone kinase inhibitors |
| EP1723126A2 (en) | 2003-10-22 | 2006-11-22 | Eli Lilly And Company | Novel mch receptor antagonists |
| JP2007519754A (ja) | 2004-01-30 | 2007-07-19 | ć¹ćć¹ćÆć©ć¤ć³ ćć¼ćć£ć ć³ć¼ćć¬ć¼ć·ć§ć³ | ååē© |
| BRPI0507495A (pt) | 2004-02-18 | 2007-07-10 | Astrazeneca Ab | composto, composiĆ§Ć£o farmacĆŖutica, uso do composto mĆ©todo para o tratamento de distĆŗrbios mediados por mglur5, e, mĆ©todo para inibir a ativaĆ§Ć£o de receptores de mglur5 |
| CN1934094A (zh) | 2004-03-05 | 2007-03-21 | äøęå¶čÆę Ŗå¼ä¼ē¤¾ | äŗč³åŗå代ęēÆ5å ēÆč”ēē© |
| CN1930136B (zh) | 2004-03-05 | 2012-02-08 | ę„äŗ§åå¦å·„äøę Ŗå¼ä¼ē¤¾ | å¼*ååå代čÆē²é °čŗååē©åę害ēē©é²é¤å |
| SE0400970D0 (sv) | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| JP2008517920A (ja) | 2004-10-25 | 2008-05-29 | ć”ć«ćÆ ćØć³ć ć«ć ććć¼ ć¤ć³ć³ć¼ćć¬ć¼ććć | 代č¬čŖæēÆåć°ć«ćæćć³é øå容ä½ć®č¤ē“ ē°å¼ć¤ć³ććć³å¢å¼·å å |
| CA2598531A1 (en) | 2005-02-24 | 2006-08-31 | Merck & Co., Inc. | Benzazole potentiators of metabotropic glutamate receptors |
| GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| JP2008540635A (ja) | 2005-05-18 | 2008-11-20 | ć¢ćććÆć¹ ćć”ć¼ć ć½ć·ćØć ć¢ććć | 代č¬åć°ć«ćæćć³é øå容ä½ć®ę£ć®ć¢ćć¹ććŖććÆčŖæēÆå åćØćć¦ć®ē½®ęććććŖćć·ćøć¢ć¾ć¼ć«čŖå°ä½ |
| TW200728277A (en) | 2005-06-29 | 2007-08-01 | Palau Pharma Sa | Bicyclic derivatives as P38 inhibitors |
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| US7868008B2 (en) * | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| WO2007021309A1 (en) | 2005-08-12 | 2007-02-22 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| CA2623721C (en) | 2005-09-27 | 2014-05-13 | F. Hoffmann-La Roche Ag | Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists |
| TW200804281A (en) * | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
| TWI417100B (zh) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | ļäŗåč”ēē©åå ¶ä½ēŗ代č¬åéŗ©čŗé øåé«å¢ęå-ļ¼ļ¼ļ¼ä¹ēØé |
| TW200911255A (en) | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
| SA109300358B1 (ar) * | 2008-06-06 | 2012-11-03 | Ų§Ų³ŲŖŲ±Ų§Ų²ŁŁŁŁŲ§ Ų§ŁŁ ŲØŁ | Ł ŁŁŁŲ§ŲŖ Ł Ų³ŲŖŁŲØŁ Ų¬ŁŁŲŖŲ§Ł Ų§ŲŖ Ų°Ł Ų§ŁŲŖŲŲ§Ų” Ų£ŁŲ¶Ł Ł Ł Ų£ŁŲ²Ł Ų„ŁŲÆŁŁŁŁ |
-
2009
- 2009-06-03 SA SA109300358A patent/SA109300358B1/ar unknown
- 2009-06-03 US US12/477,347 patent/US7790760B2/en not_active Expired - Fee Related
- 2009-06-04 TW TW101129417A patent/TWI477499B/zh not_active IP Right Cessation
- 2009-06-04 TW TW098118593A patent/TWI382027B/zh not_active IP Right Cessation
- 2009-06-04 TW TW103145569A patent/TW201514173A/zh unknown
- 2009-06-05 AR ARP090102031A patent/AR072016A1/es unknown
- 2009-06-05 UY UY0001031870A patent/UY31870A/es not_active Application Discontinuation
- 2009-06-08 PL PL09758630T patent/PL2303872T3/pl unknown
- 2009-06-08 EP EP09758630.9A patent/EP2303872B1/en active Active
- 2009-06-08 UA UAA201014034A patent/UA107649C2/uk unknown
- 2009-06-08 KR KR1020107027224A patent/KR20110020797A/ko not_active Abandoned
- 2009-06-08 EA EA201300342A patent/EA201300342A1/ru unknown
- 2009-06-08 CA CA2726925A patent/CA2726925A1/en not_active Abandoned
- 2009-06-08 CN CN200980129149.7A patent/CN102105466B/zh not_active Expired - Fee Related
- 2009-06-08 WO PCT/SE2009/050682 patent/WO2009148403A1/en not_active Ceased
- 2009-06-08 JP JP2011512416A patent/JP5476371B2/ja not_active Expired - Fee Related
- 2009-06-08 SI SI200930928T patent/SI2303872T1/sl unknown
- 2009-06-08 BR BRPI0913585A patent/BRPI0913585A2/pt not_active IP Right Cessation
- 2009-06-08 EP EP14164664.6A patent/EP2772492B1/en active Active
- 2009-06-08 HR HRP20140451AT patent/HRP20140451T1/hr unknown
- 2009-06-08 MY MYPI2010005780A patent/MY156552A/en unknown
- 2009-06-08 ES ES09758630.9T patent/ES2469837T3/es active Active
- 2009-06-08 DK DK09758630.9T patent/DK2303872T3/da active
- 2009-06-08 PT PT97586309T patent/PT2303872E/pt unknown
- 2009-06-08 RS RS20140295A patent/RS53392B/sr unknown
- 2009-06-08 PE PE2010001111A patent/PE20110028A1/es not_active Application Discontinuation
- 2009-06-08 MX MX2010012949A patent/MX2010012949A/es active IP Right Grant
- 2009-06-08 AU AU2009255784A patent/AU2009255784B2/en not_active Ceased
- 2009-06-08 NZ NZ590344A patent/NZ590344A/en not_active IP Right Cessation
- 2009-06-08 EA EA201001724A patent/EA018412B1/ru not_active IP Right Cessation
- 2009-10-08 US US12/575,891 patent/US7781434B2/en not_active Expired - Fee Related
-
2010
- 2010-08-13 NI NI201000209A patent/NI201000209A/es unknown
- 2010-08-20 US US12/860,330 patent/US8148372B2/en not_active Expired - Fee Related
- 2010-08-26 US US12/869,263 patent/US7888353B2/en not_active Expired - Fee Related
- 2010-11-26 CO CO10149429A patent/CO6321239A2/es active IP Right Grant
- 2010-11-29 IL IL209622A patent/IL209622A0/en unknown
- 2010-11-30 ZA ZA2010/08611A patent/ZA201008611B/en unknown
- 2010-12-03 CL CL2010001348A patent/CL2010001348A1/es unknown
- 2010-12-06 DO DO2010000375A patent/DOP2010000375A/es unknown
- 2010-12-06 GT GT201000342A patent/GT201000342A/es unknown
- 2010-12-06 NI NI2010002092A patent/NI201002092A/es unknown
- 2010-12-06 CR CR11826A patent/CR11826A/es unknown
- 2010-12-06 CU CU20100238A patent/CU23883B1/es not_active IP Right Cessation
- 2010-12-06 NI NI2010002091A patent/NI201002091A/es unknown
- 2010-12-06 SV SV2010003751A patent/SV2010003751A/es not_active Application Discontinuation
- 2010-12-06 HN HN2010002582A patent/HN2010002582A/es unknown
- 2010-12-07 EC EC2010010662A patent/ECSP10010662A/es unknown
-
2014
- 2014-02-06 JP JP2014020956A patent/JP5815765B2/ja not_active Expired - Fee Related
- 2014-06-11 CY CY20141100416T patent/CY1115301T1/el unknown
-
2015
- 2015-02-13 HK HK15101607.6A patent/HK1201255A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| CO6300954A2 (es) | Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk | |
| PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
| PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| PE20081229A1 (es) | Antagonistas de receptor de orexina de diazepam sustituido | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| PE20141228A1 (es) | Derivados de pirrolopirimidina y purina | |
| PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
| PE20121158A1 (es) | Derivados de feniletinilo como moduladores alostericos positivos (map) | |
| PE20070585A1 (es) | Derivados de sulfonamida como activadores de glucoquinasa | |
| PE20081800A1 (es) | NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| PE20080150A1 (es) | Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch) | |
| PE20110852A1 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
| ECSP10010654A (es) | Derivados de tienopiridonas como activadores de proteĆna quinasa activados por amp (ampk) | |
| DOP2007000018A (es) | Moduladores de indol sulfonamida de receptores de progesterona | |
| PE20120561A1 (es) | Compuestos que modulan selectivamente el receptor cb2 | |
| PE20071156A1 (es) | COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) | |
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20110196A1 (es) | 5-alquinil-pirimidinas | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| PE20081753A1 (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |